Ono Kenjiro
Division of Neurology, Department of Medicine, Showa University School of Medicine.
Brain Nerve. 2020 Feb;72(2):137-141. doi: 10.11477/mf.1416201493.
Although α-synuclein protein (αS) undergoes aggregation from a monomer to assemblies, such as oligomers, protofibrils, and mature fibrils, the early intermediate aggregates, that is, oligomers, are considered to be the most toxic species in the pathogenesis of α-synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). While it has been reported that the αS concentration in cerebrospinal fluid (CSF) is decreased significantly in patients with PD and DLB, there have been reports of the αS oligomer concentration being elevated in the CSF of patients with PD. Moreover, it is supposed that the αS oligomer concentration is also elevated in the blood of patients with PD. Recently, it has been reported that lower cerebrospinal β-amyloid (Aβ)1-40, Aβ1-42, and αS levels are associated with cognitive decline in PD. Further combination studies of the CSF and blood may lead to the establishment of the candidate αS as a biomarker for α-synucleinopathies, including PD and DLB.
尽管α-突触核蛋白（αS）会从单体聚集成诸如寡聚体、原纤维和成熟纤维等聚集体，但早期中间聚集体，即寡聚体，被认为是包括帕金森病（PD）和路易体痴呆（DLB）在内的α-突触核蛋白病发病机制中最具毒性的物质。虽然有报道称PD和DLB患者脑脊液（CSF）中的αS浓度显著降低，但也有报道称PD患者脑脊液中的αS寡聚体浓度升高。此外，据推测PD患者血液中的αS寡聚体浓度也会升高。最近，有报道称脑脊液中较低的β-淀粉样蛋白（Aβ）1-40、Aβ1-42和αS水平与PD患者的认知功能下降有关。脑脊液和血液的进一步联合研究可能会导致将αS确立为包括PD和DLB在内的α-突触核蛋白病的候选生物标志物。
